COST-EFFECTIVENESS ANALYSIS PENGOBATAN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PADA PASIEN RAWAT INAP DI RSUD DOKTER SOEKARDJO KOTA TASIKMALAYA

Karmila, Eli (2021) COST-EFFECTIVENESS ANALYSIS PENGOBATAN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PADA PASIEN RAWAT INAP DI RSUD DOKTER SOEKARDJO KOTA TASIKMALAYA. Sarjana thesis, STIKes BTH Tasikmalaya.

	Text (Cover dan Abstrak) Cover dan Abstrak.pdf Download (50kB)
	Text (BAB I - BAB V) BAB I - BAB V.pdf Restricted to Repository staff only Download (606kB)
	Text (Daftar Pustaka) Daftar Pustaka.pdf Download (123kB)

Abstract

ABSTRAK COST-EFFECTIVENESS ANALYSIS PENGOBATAN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PADA PASIEN RAWAT INAP DI RSUD DOKTER SOEKARDJO KOTA TASIKMALAYA Eli Karmila S1 Farmasi, STIKes Bakti Tunas Husada Tasikmalaya ABSTRAK Gastroesophageal Reflux Disease (GERD) adalah suatu kondisi patologis dimana isi lambung mengalami refluks secara berulang ke esofagus akibat melemahnya tekanan sfingter, yang menyebabkan heartburn dan regurgitasi. Penelitian ini bertujuan untuk mengetahui obat yang paling cost-effective berdasarkan nilai Average Cost-Effectiveness Ratio (ACER) dan Incremental Cost-Effectiveness Ratio (ICER) pada pasien GERD. Penelitian ini merupakan penelitian observasional deskriptif secara retrospektif. Penelitian dilakukan pada bulan Januari sampai Maret 2021. Data diambil dari rekam medis kelas III dengan diagnosis GERD. Hasil penelitian menunjukkan bahwa 40 pasien memenuhi kriteria inklusi. Selain itu kombinasi omeprazol kapsul dan sukralfat suspensi memiliki nilai ACER paling rendah, berdasarkan target terapi dan lama perawatan masing-masing sebesar Rp.1.371.499,60 dan Rp.2.285.832,66. Nilai ICER kombinasi omeprazole kapsul dan sukralfat suspensi dapat menghemat biaya sebesar Rp.18.296.196,69. Kombinasi omeprazole kapsul dan sukralfat suspensi merupakan obat yang paling cost-effective. Kata Kunci: Analisis Efektivitas-Biaya, Farmakoekonomi, Penyakit Refluks Esofagus. ABSTRACT Gastroesophageal Reflux Disease (GERD) is a pathological condition where the gastric contents reflux repeatedly into the esophagus due to weakened sphincter pressure, that causing of heartburn and regurgitation. The objective of the study was to determine the cost-effectiveness analysis of Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER) in GERD patients. This study was descriptive observational retrospective. The study was conducted from January to March 2021.The data were taken from medical records from class III with GERD diagnosis. The results showed 40 patients were met inclusion criteria. Moreover the combination of omeprazole capsule and sucralfate suspension had the lowest ACER value based on therapeutic target and length of treatment as Rp.1.371,499.60 and Rp.2.285.832,66, respectively. The ICER value of omeprazole capsule and sucralfate suspension combination saving money Rp.18.296.196,69. Combination of omeprazole capsule and sucralfate suspension is the most cost-effective drug. Keywords: Cost-Effectiveness Analysis, Gastroesophageal Reflux Disease, Pharmacoeconomy.

Actions (login required)

View Item